Ambu (AMBU) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary
Event summary combining transcript, slides, and related documents.
43rd Annual J.P. Morgan Healthcare Conference 2025 summary
10 Jan, 2026Business performance and market overview
Achieved close to 20% growth in endoscopy solutions and completed a business turnaround, positioning for further market leadership in single-use endoscopy.
Single-use endoscopes accounted for two-thirds of all such procedures globally in 2024, with 2.4 million procedures performed.
The addressable market is about 100 million annual procedures, with less than 4% currently using single-use devices; current portfolio serves 23 million procedures.
Endoscopy solutions now represent 60% of total revenue, with North America contributing about half of overall revenue.
Five-year revenue CAGR stands at 14%, with endoscopy solutions growing at 28% CAGR, more than tripling revenue in that segment.
Strategic initiatives and operational improvements
The "Zoom In" strategy, launched two years ago, focused on targeted growth, execution, and sustainability, delivering significant EBIT margin improvement of over nine percentage points.
All single-use endoscopes converted to bioplastic within 12 months, with ongoing sustainability initiatives and SBTi-validated emission targets.
Achieved positive free cash flow and became debt-free, enabling greater investment in growth.
Transformation program brought new management capabilities and operational model updates, supporting scalable growth.
Segment performance and innovation
Pulmonology returned to double-digit growth (11.7%) after post-COVID turbulence; other segments (urology, ENT, GI) grew nearly 30%.
Maintains leadership in single-use endoscopy across all four segments, with highest penetration in pulmonology and growing presence in urology, ENT, and GI.
Workflow efficiency, cost savings, and sustainability are key drivers for adoption, with single-use endoscopes offering lower CO2 footprint than reusables.
New product launches include a video laryngoscope for pulmonology and high-definition cystoscope and ureteroscope for urology, all integrated on a single software platform.
AI and software advancements are expected to further enhance image quality and reduce costs, supporting future growth.
Latest events from Ambu
- Q1 delivered 8.6% organic revenue growth and 10.5% EBIT margin, led by Endoscopy Solutions.AMBU
Q1 25/264 Feb 2026 - Q3 saw 15% organic growth, margin expansion, and upgraded guidance on strong segment performance.AMBU
Q3 23/2422 Jan 2026 - Strong growth and profitability, with robust outlook despite GI impairment.AMBU
Q4 23/2417 Jan 2026 - Leading single-use endoscopy with 60%+ share, targeting double-digit growth and margin expansion.AMBU
SEB Nordic Seminar presentation16 Jan 2026 - Double-digit growth and innovation drive global endoscopy leadership ambitions.AMBU
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Q1 2024/25 saw 19.5% organic growth, margin expansion, and upgraded guidance.AMBU
Q1 24/259 Jan 2026 - 12% organic growth in Q3, raised guidance, and strong segment momentum despite FX headwinds.AMBU
Q3 24/2523 Nov 2025 - Q2 organic revenue up 11.7% and EBIT margin at 14.4%, with guidance reaffirmed.AMBU
Q2 24/2519 Nov 2025 - 13.1% organic growth and 13.0% EBIT margin, with robust outlook despite FX and tariff headwinds.AMBU
Q4 24/255 Nov 2025